Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles
Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disorder due to the deficit of the enzyme iduronate 2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans in most organ-systems, including the brain, and resulting in neurological involvement in about two-thirds of the p...
Main Authors: | Laura Rigon, Marika Salvalaio, Francesca Pederzoli, Elisa Legnini, Jason Thomas Duskey, Francesca D’Avanzo, Concetta De Filippis, Barbara Ruozi, Oriano Marin, Maria Angela Vandelli, Ilaria Ottonelli, Maurizio Scarpa, Giovanni Tosi, Rosella Tomanin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/8/2014 |
Similar Items
-
Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients
by: Rossella Parini, et al.
Published: (2015-06-01) -
PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study
by: Gina P. Hoyos-Ceballos, et al.
Published: (2020-01-01) -
Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy
by: Stuart Ellison, et al.
Published: (2023-12-01) -
Investigating Novel Syntheses of a Series of Unique Hybrid PLGA-Chitosan Polymers for Potential Therapeutic Delivery Applications
by: Jason Thomas Duskey, et al.
Published: (2020-04-01) -
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders.
by: Marika Salvalaio, et al.
Published: (2016-01-01)